CF
CLSD

Centaurus Financial’s Clearside Biomedical CLSD Stock Holding History

Centaurus Financial’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10
Closed -$2K – 788
2018
Q2 		$2K Buy
+10
New +$1.69K ﹤0.01% 1995

Other funds holding CLSD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
NC
Northpointe Capital Bloomfield Hills, Michigan $258M AUM 1.97% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return

Centaurus Financial's CLSD Position: Q3 2018 in Review

Centaurus Financial sold out of Clearside Biomedical (CLSD) in Q3 2018, closing a stake of 10 shares — an estimated $2K sold.

Centaurus Financial first reported a position in CLSD in Q2 2018 and held it in 1 quarter. The position peaked at $2K in Q2 2018. 89 funds tracked by Wall St. Rank hold CLSD as of Q3 2018.

  • Centaurus Financial reported no remaining Clearside Biomedical position as of Q3 2018 after selling out during the quarter.
  • Centaurus Financial sold 10 Clearside Biomedical shares in Q3 2018, an estimated $2K.
  • Centaurus Financial first reported a position in Clearside Biomedical in Q2 2018 and held it in 1 quarter.
  • Centaurus Financial's Clearside Biomedical position peaked at $2K in Q2 2018.
  • 89 funds tracked by Wall St. Rank held Clearside Biomedical as of Q3 2018.

Based on Centaurus Financial's 13F filing for Q3 2018, filed 5 Nov 2018.